ClinConnect ClinConnect Logo
Search / Trial NCT06233708

Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant

Launched by ASAN MEDICAL CENTER · Jan 28, 2024

Trial Information

Current as of June 22, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult patients
  • Underwent liver transplantation for treating hepatocellular carcinoma
  • Between Jan. 2008 - May. 2022
  • Exclusion Criteria:
  • Pediatric patients (Age under 18 years)
  • Re-transplantation
  • Multi-organ transplantation

About Asan Medical Center

Asan Medical Center, located in Seoul, South Korea, is a leading healthcare institution renowned for its commitment to advanced medical research and patient care. With a focus on innovative clinical trials, the center aims to enhance healthcare outcomes through rigorous scientific investigation and collaboration. Asan Medical Center is equipped with state-of-the-art facilities and a multidisciplinary team of experts dedicated to exploring new therapeutic approaches across various medical fields. Its robust infrastructure supports a wide range of clinical studies, contributing significantly to the global medical community's understanding of diseases and treatment efficacy.

Locations

Patients applied

0 patients applied

Trial Officials

Jun-Gol Song, MD, PhD

Study Chair

Department of Anesthesiology and Pain Medicine, Asan Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported